Patients who may benefit can include patients with: *Hyperphosphatemia *corrected calcium below target levels or symptomatic hypocalcemia *Hypercalcuria or nephrolithiasis despite thiazide use …

Dec 19, 2024 · Reflecting this commitment, Ascendis has established a dedicated YORVIPATH team within the U.S. Ascendis Signature Access Program ® to support the patient treatment journey, …

Feb 13, 2025 · Is Yorvipath Right for Me? Your health care provider may consider treatment with Yorvipath if you have hypoparathyroidism and have been taking calcium and vitamin D treatment.

Our commitment to patients is reflected in our core values and we do our best every day to realize our products' benefits for patients.

Yorvipath® is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults. Conventional therapy for hypoparathyroidism consists of active vitamin …

Mar 14, 2025 · Yorvipath (palopegteriparatide) is a prescription injection that treats hypoparathyroidism in adults, Learn about dosage, side effects, cost, uses, and more.

POLICY STATEMENT Prior Authorization is recommended for prescription benefit coverage of Yorvipath. All approvals are provided for the duration noted below. Because of the specialized skills …

Aug 14, 2024 · The company, through its U.S. Ascendis Signature Access Program, plans to offer patient services such as support for navigating treatment and financial assistance for eligible …

Aug 13, 2024 · Yorvipath (palopegteriparatide) is a long-acting parathyroid hormone analog that releases PTH (1-34) throughout the day, which temporarily restores physiologic levels of parathyroid …

Aug 12, 2024 · At launch, Ascendis plans to offer a suite of patient services for YORVIPATH through its U.S. Ascendis Signature Access Program (A.S.A.P.), including support navigating the treatment …